Important matters:
Goli Pharmaceutical-B (01672): Goli will present research results on the oral small molecule GIPR agonist ASC48 and GLP-1R/GIPR/GCGR three-target agonist polypeptide ASC37 (ObesityWeek®) 2026 (ObesityWeek®)
Xiansheng Pharmaceutical (02096) and Lingke Pharmaceutical signed an exclusive promotion service agreement for zepciitinib's pictorial indications
Shoucheng Holdings (00697) subsidiary plans to subscribe up to HK$83.95 million for up to 13.432 million shares to be sold by First Fidelity Finance
Jinhai Medical Technology (02225) and Shenzhou Medical signed a strategic memorandum of cooperation to explore business operation mergers and acquisitions and equity investment cooperation
Kaituo Pharmaceutical-B (09939): KX-826 tincture 1.0% long-term safety clinical trial completed for androgen hair loss in adult Chinese men
Hong Kong Gold Industry Group (02623) plans to increase its holdings of MJS shares by HK$92.3462 million and increase its shareholding to 9.45%
Shenyan Intelligence (02723) signs strategic cooperation with Baidu Intelligent Cloud to promote integrated AI decision-making solutions
Wanwuyun (02602) entered into a series of debt settlement agreements involving about $662 million
Junzhi Group (01300) won the pre-bid for China Telecom's centralized procurement project for feeders and accessories products (2026-2028)
Shiyao Group (01093): Phase III clinical trial of plugliptin tablets combined with dapagliflozin tablets and metformin hydrochloride extended-release tablets for the treatment of type 2 diabetes achieved positive top-line results
Shoujia Technology (00103) plans to establish a joint research institute for new materials with Xi'an Jiaotong University
Operating performance:
Fuwei Group (01828)'s service margin for new business contracts increased 22% year-on-year to US$1.4 billion in the first three quarters
Tianshu Zhixin (09903) has shipped more than 80,000 chips in the first 10 months
Hantian Tiancheng (02726) is expecting net profit for the 2026 fiscal year to be about 108 million yuan to 158 million yuan, a year-on-year increase of about 800% to 1217%
Hard Egg Innovation (00400)'s revenue for the first three quarters was about 20.916 billion yuan, an increase of about 109.0%